Company Overview and News

 
Elpro International to sell nearly 1.33 per cent stake in PNB MetLife

2018-05-08 thehindubusinessline
Elpro International has agreed to sell approximately 1.33 per cent shareholding in PNB MetLife India Insurance Company for a total consideration of ₹134.22 crore. The decision is subject to satisfaction of certain conditions, including approval from the Insurance Regulatory and Development Authority of India and the Competition Commission of India. Elpro International has been holding 12.75 per cent stake in PNB MetLife Insurance since 2003.

 
Cresta Fund sells 19.76 lakh shares of Elpro International

2018-03-28 moneycontrol
On March 27, 2018 Cresta Fund sold 19,76,851 shares of Elpro International at Rs 48 on the BSE.

 
Elpro’s ₹100-crore rights issue opens

2018-03-27 thehindubusinessline
The rights issue of Elpro International will open on Wednesday and close on April 11. It plans to raise up to ₹100 crore through the rights issue by offering 3.11 crore shares at ₹32.10 a share. The entitlement ratio is nine equity shares for every 40 held by existing shareholders in the company as on February 9. Meanwhile, exchange disclosures reveal that its promoters have been increasing their stakes in the firm through creeping acquisitions in the last few days.

 
The top buzzing midcap stocks to trade on March 19

2018-03-20 moneycontrol
Here are some of the top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. Keep an eye on Cipla, Elpro International, Gujarat State Petroleum Corporation (GSPL) and Binani Industries.

 
Elpro to sell 1.25% equity in MetLife for Rs 125 crore

2018-03-19 moneycontrol
Elpro International today said it will offload 1.25 percent of its equity stake in PNB MetLife insurance company, which may fetch it about Rs 125 crore.

 
Elpro International turns ex-stock split

2017-09-27 indiainfoline
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in “National Do Not Call Registry” as laid down by “Telecom Regulatory Authority of India” will not be applicable for such information/ communication.

 
Company news

2017-07-25 thehindubusinessline
Websol Energy Systems on Tuesday expressed its regret for not announcing its Q1 results, which was originally scheduled to be announced on July 25, due to delay in implementing the new accounting policy required under IND AS. However, it said it was ‘pleased’ to inform the bourses that ‘no dues’ certificate from Federal Bank has been taken on record. The board has approved another expansion of 100 MW of its cell line capacity, thereby taking it to 280-300 MW.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

23h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

23h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...